Milella, Michele
 Distribuzione geografica
Continente #
EU - Europa 5.271
NA - Nord America 5.235
AS - Asia 3.261
AF - Africa 75
SA - Sud America 40
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 7
AN - Antartide 1
Totale 13.907
Nazione #
US - Stati Uniti d'America 5.169
CN - Cina 1.608
SG - Singapore 1.160
GB - Regno Unito 800
RU - Federazione Russa 785
FR - Francia 771
IT - Italia 767
IE - Irlanda 699
SE - Svezia 552
DE - Germania 398
FI - Finlandia 257
ID - Indonesia 142
HK - Hong Kong 85
UA - Ucraina 68
VN - Vietnam 63
CA - Canada 59
TG - Togo 50
KR - Corea 39
JP - Giappone 35
NL - Olanda 33
IN - India 32
PL - Polonia 28
CZ - Repubblica Ceca 24
TH - Thailandia 23
BR - Brasile 19
AU - Australia 17
EG - Egitto 15
IR - Iran 15
BE - Belgio 13
AT - Austria 12
MY - Malesia 10
ES - Italia 9
CH - Svizzera 8
EU - Europa 7
PE - Perù 7
AZ - Azerbaigian 6
CL - Cile 6
LU - Lussemburgo 6
SK - Slovacchia (Repubblica Slovacca) 6
TR - Turchia 6
KG - Kirghizistan 5
LV - Lettonia 5
MA - Marocco 5
RO - Romania 5
BG - Bulgaria 4
CO - Colombia 4
HR - Croazia 4
MK - Macedonia 4
PH - Filippine 4
PK - Pakistan 4
AM - Armenia 3
DK - Danimarca 3
EC - Ecuador 3
IL - Israele 3
AE - Emirati Arabi Uniti 2
BY - Bielorussia 2
CR - Costa Rica 2
GR - Grecia 2
JO - Giordania 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
MX - Messico 2
NO - Norvegia 2
PA - Panama 2
SA - Arabia Saudita 2
TN - Tunisia 2
TW - Taiwan 2
UZ - Uzbekistan 2
BD - Bangladesh 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
FK - Isole Falkland (Malvinas) 1
GS - Georgia del Sud e Isole Sandwich Australi 1
HU - Ungheria 1
IQ - Iraq 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LT - Lituania 1
MD - Moldavia 1
PT - Portogallo 1
SC - Seychelles 1
ZA - Sudafrica 1
Totale 13.907
Città #
Chandler 1.264
Singapore 964
Southend 738
Dublin 677
Beijing 336
Woodbridge 333
Jacksonville 299
Ashburn 294
Lawrence 267
Princeton 267
Verona 264
Ann Arbor 197
Sindelfingen 185
Houston 171
Redmond 139
Jakarta 137
Wilmington 135
Jinan 134
Helsinki 114
New York 106
Nanjing 84
Hong Kong 76
Shenyang 74
Milan 68
Hebei 61
Seattle 59
Lomé 50
Tianjin 48
Ningbo 44
Toronto 41
Changsha 37
Seoul 37
Los Angeles 33
Santa Clara 33
Boardman 31
Haikou 31
Hangzhou 31
Kent 31
Zhengzhou 31
Nanchang 30
Dallas 29
Dong Ket 29
Tokyo 29
Washington 27
Moscow 25
Redwood City 25
Taiyuan 25
Taizhou 25
Guangzhou 24
Munich 23
Fuzhou 22
Jiaxing 22
Rome 22
Bangkok 21
Andover 20
Brno 20
Lanzhou 20
Amsterdam 18
Chicago 18
Dongguan 17
Lappeenranta 17
San Francisco 16
Fairfield 14
Brussels 13
London 13
Falls Church 12
Shanghai 12
Cedar Knolls 11
Norwalk 11
Bologna 10
Cairo 9
Cambridge 9
Padova 9
Paris 9
Trento 9
Vienna 9
Zanjan 9
Falkenstein 8
Frankfurt am Main 8
Huskvarna 8
Boydton 7
Chions 7
Clearwater 7
Este 7
Kochi 7
Laurel 7
Lima 7
São Paulo 7
Baku 6
Dearborn 6
Isola della Scala 6
Mehlingen 6
Menlo Park 6
Mumbai 6
Pieve di Soligo 6
Adelaide 5
Bishkek 5
Bussolengo 5
Ferrara 5
Melbourne 5
Totale 8.751
Nome #
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 121
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease 120
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 110
Genomic characterization of hepatoid tumors: context matters 110
Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models 106
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 101
ERK 1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia 100
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 100
"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients 97
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models 93
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer 93
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 92
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg 92
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial 92
An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen 91
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 89
Sex differences in oncogenic mutational processes 87
Long-Term Patient-Centred Follow-up in a Prospective Cohort of Patients with COVID-19 83
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 82
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 79
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 79
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 79
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 78
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 78
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma 77
Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules 77
Circulating autoantibodies to phosphorylated alpha-enolase are a hallmark of pancreatic cancer 75
From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer 75
Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions 75
An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change? 74
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients 74
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 73
Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours 73
Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma 72
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 72
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples 71
Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder 70
Psychological impact of Covid-19 pandemic on oncological patients: a survey in Northern Italy 70
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 69
Do immune checkpoint inhibitors need new studies methodology? 69
Novel Clinical Prognostic Score Incorporating the Number of Resected Lymph-Nodes to Predict Recurrence and Survival in Non-Small-Cell Lung Cancer. 68
The Italian Rare Pancreatic Exocrine Cancer Initiative 68
Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer 68
Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report 68
Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer 68
Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. 67
Aromatase inhibitors in post-menopausal metastatic breast carcinoma 67
Cardiotoxicity and Incidence Of Brain Metastases After Adjuvant Trastuzumab for Early Breast Cancer: The Dark Side of the Moon? A Meta-Analysis of The Randomized Trials. 66
The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome 66
JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer 66
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 65
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 65
Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice? 65
Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients 64
Muscle derangement and alteration of the nutritional machinery in NSCLC 64
Autoantibody signature in human ductal pancreatic adenocarcinoma 64
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 64
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. 63
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. 63
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 63
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 63
Metastatic pancreatic cancer: Is there a light at the end of the tunnel? 62
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 62
Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine 62
Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward 62
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 61
Physical activity and exercise in lung cancer care: will promises be fulfilled? 61
Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets 61
Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. 60
Exercise levels and preferences in cancer patients: a cross-sectional study 60
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma 60
Factors influencing physical activity in cancer patients during oncological treatments: a qualitative study 60
A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma 60
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 60
Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability 60
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients 60
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 59
Pan-cancer analysis of whole genomes 59
Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib 59
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. 59
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 59
Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial 59
Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona 59
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma 58
Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer 58
ASO Author Reflections: Preoperative Nutritional Care: The 'Cinderella' of Surgical Management in Patients with Pancreatic Cancer 58
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities 58
Signal transduction pathways as therapeutic targets in cancer therapy 57
IL CARCINOMA POLMONARE A GRANDI CELLULE 57
Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to Raise the Bar 57
Targeting KRAS: The Elephant in the Room of Epithelial Cancers 57
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer 57
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. 55
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss 55
The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer 55
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 55
"Pure" hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms 55
Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology 54
Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites 54
Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective, multicenter analysis 53
Totale 7.070
Categoria #
all - tutte 72.972
article - articoli 72.371
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 601
Totale 145.944


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020448 0 0 0 0 47 50 38 36 52 51 57 117
2020/20211.111 93 259 52 122 146 119 37 34 43 25 110 71
2021/20221.789 110 378 60 108 46 22 37 103 59 37 310 519
2022/20234.070 290 364 383 714 323 1.057 61 223 440 49 105 61
2023/20242.607 91 167 234 360 225 356 206 191 56 126 419 176
2024/20252.814 438 354 332 1.393 297 0 0 0 0 0 0 0
Totale 14.355